A Chinese-developed Covid-19 vaccine candidate triggered a quick immune response in early trials, but the level of antibodies produced was below that of a person recovering from the disease, a study has shown.
一項研究顯示，中國研製的一種新型冠狀病毒肺炎（COVID-19，即2019冠狀病毒病）候選疫苗在早期試驗中引發了快速的免疫反應，但其產生的抗體水準低於正在康復的新冠患者。
您已閱讀12%（294字），剩餘88%（2214字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。
